Smithkline Beckman Corp, part of GSK Plc, is an American company located in Philadelphia, PA, involved in pharmaceutical preparations. On July 27, 1989 Smithkline Beecham Plc acquired Smithkline Beckman Corp for $16,082.37 million.

Araim Pharmaceuticals, Inc. operates as a biotechnology company that develops novel treatments for devastating injuries and chronic diseases. It provides ARA 290, a novel 11 amino acid peptide that activates the body’s natural repair system through the innate repair receptor, which is present only following injury, as well as activates anti-inflammatory, tissue protective, and reparative signaling pathways. The company was founded by Anthony Cerami and Michael Brines in 2006 and is headquartered in Tarrytown, NY.

Takeda Austria GmbH, part of Takeda Pharmaceutical Co., Ltd., is an Austrian company located in Linz. The firm engages in research and development of pharmaceutical products. Kirsten Detrick has been the CEO since 2016.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Coley Pharmaceutical GmbH, part of Pfizer Inc., is a German company located in Berlin that provides research and development in the field of natural sciences, engineering, agricultural sciences and medicine. It was founded by Heather L. Davis.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

SyStemix develops cellular and cell-based gene therapies for cancer, AIDS, and genetic diseases based on the use of isolated, expanded, and gene-modified hematopoietic stem cells. The company is based in Palo Alto, California. SyStemix, Inc. was acquired by Novartis AG. In February 1997, SyStemix completed a merger with Novartis Biotech Holding Corp., an indirect wholly owned subsidiary of Novartis, Inc. Novartis shuttered Systemix in 2000.

Telik, Inc. is an innovative biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. Its TELINTRA product is used for treatment of cytopenias due to myelodysplastic syndrome and chemotherapy. The company's product candidates were discovered using its proprietary drug discovery technology TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Telik was founded in September 1988 and is headquartered in Palo Alto, CA.

Nycomed is a privately owned global pharmaceutical company with a diversified portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. A range of OTC products completes the portfolio. Its R&D is structured around collaborations. In-licensing and expanding in emerging markets are cornerstones of the company's growth strategy. Nycomed employs 12,500 associates worldwide, and its products are sold in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS, Latin America, Asia and the Middle East. In the US and Japan its products are available through best in class partners. Headquartered in Zurich, Switzerland, the company generated total sales of € 3.2 billion in 2010 and an adjusted EBITDA of € 851 million.

ARCH Development Corp., part of The University of Chicago, is an American company that provides job training and housing development services. Duane Gautier is currently the CEO of the firm.

Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changed its name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc.

Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. - Identify and assess research projects with commercial potential. - Protect the intellectual property of the Institute and its scientists. - Create business relationships and license the Institute’s inventions and technologies to the industry. - Channel funding from industry to research projects. For further information please contact Tamir Huberman, CIO and Head of Marketing

The Eli and Edythe L. Broad Institute of MIT and Harvard (/ˈbroʊd/), often referred to as the Broad Institute, is a biomedical and genomic research center located in Cambridge, Massachusetts, United States. The institute is independently governed and supported as a 501(c)(3) nonprofit research organization under the name Broad Institute Inc., and is partners with Massachusetts Institute of Technology, Harvard University, and the five Harvard teaching hospitals.

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

Formed in 1985, the University of Maryland Biotechnology Institute (UMBI) is part of the University System of Maryland. It was created to provide a unified focus for Maryland's biotechnology research and education.

Privately held biotechnology company developing protein therapeutics that address unmet clinical and societal needs in the areas of Oncology, Hematology and Immunology

The Istituto Superiore di Sanità (Italian National Institute of Health), also ISS, is an Italian public institution that, as the leading technical-scientific body of the Italian National Health Service (Servizio Sanitario Nazionale), performs research, trials, control, counseling, documentation and training for public health. The Institute is under the supervision of the Ministero della Salute (Ministry of Health).

Leibniz Institute for Polymer Research Dresden provides research and analysis services by incorporating state-of-the-art technology.

Menarini Ricerche SpA provides research and development activities in the pharmaceutical sector. It involves in the full spectrum starting with the initial stages of research and the clinical trial phases up to industrial production as well as patent protection regulation. The company was founded in 1978 and is headquartered in Pomezia, Italy.